Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive topline results from a placebo-controlled Phase 2/3 study evaluating fasinumab in patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE